An immunological biomarker to predict MTX response in early RA

Objectives The therapeutic goal for patients with rheumatoid arthritis (RA) is clinical remission. This is best achieved by early diagnosis and appropriate therapeutic intervention. RA is associated with dysregulation of T-cell subsets (naïve, regulatory (Treg) and inflammation-related cells (IRC)) early in the disease. Our aim was to test the hypothesis that T-cell subset quantification can predict the achievement of clinical remission with early treatment in RA. Methods T-cell subsets were quantified in 108 drug-naïve, early RA patients commencing methotrexate (MTX) or MTX+antitumor necrosis factor (anti-TNF) and in 105 healthy controls (HC). The primary outcome assessed was remission (DAS28<2.6). A pilot study used frozen cells (38 patients and 35 HCs, see online supplementary material) and was validated with fresh blood (70 patients and 70 HCs). Results Immune dysregulation in early RA was confirmed with an association between age and reduced naïve cells compared with HCs (p=0.006), a lower age-adjusted Treg and higher IRC frequency (p=0.001). Anticitrullinated peptide antibody (ACPA) positivity was associated with lower naïve (p=0.031) and Treg frequencies (p=0.039). In 50 patients treated with MTX, ACPA/age-adjusted analysis demonstrated that higher naïve cell frequency (relative to HC) was associated with remission (OR 5.90 (1.66 to 20.98), p=0.006, sensitivity/specificity 62%/79%, Positive Predictive Value (PPV)/Negative Predictive Value (NPV) 66%/76%). Remission with MTX+anti-TNF (n=20) was not found to be associated with naïve cell frequency, and for patients with reduced naïve cells the remission rate increased from 24% (MTX) to 42% (MTX+anti-TNF). Conclusions Baseline T-cell subset analysis has a value in predicting early RA remission with first therapy with MTX. Immunological analysis could be used in conjunction with clinical/serological features to predict response to MTX and help select the most appropriate therapy at disease presentation.

[1]  P. Emery,et al.  Combination etanercept and methotrexate provides better disease control in very early (≤4 months) versus early rheumatoid arthritis (>4 months and <2 years): post hoc analyses from the COMET study , 2012, Annals of the rheumatic diseases.

[2]  F. Ponchel,et al.  CD4+ T-cell subsets in rheumatoid arthritis , 2012 .

[3]  C. Bombardier,et al.  Predictors for remission in rheumatoid arthritis patients: A systematic review , 2010, Arthritis care & research.

[4]  John Wong,et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs , 2010, Annals of the rheumatic diseases.

[5]  P. Emery,et al.  Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped? , 2010, Annals of the rheumatic diseases.

[6]  Maurizio Cutolo,et al.  Treating rheumatoid arthritis to target: recommendations of an international task force , 2010, Annals of the rheumatic diseases.

[7]  F. Breedveld,et al.  Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial , 2008, The Lancet.

[8]  Sarah L. Field,et al.  Abnormal T cell differentiation persists in patients with rheumatoid arthritis in clinical remission and predicts relapse , 2007, Annals of the rheumatic diseases.

[9]  M. Ahlmén,et al.  Sex: a major predictor of remission in early rheumatoid arthritis? , 2006, Annals of the rheumatic diseases.

[10]  A. Silman,et al.  Predictors of Response to Anti-tnf-therapy among Patients with Rheumatoid Arthritis: Results from the British Society for Rheumatology Biologics Register , 2022 .

[11]  P. Emery,et al.  Early rheumatoid arthritis is associated with a deficit in the CD4+CD25high regulatory T cell population in peripheral blood. , 2006, Rheumatology.

[12]  T. Gingeras,et al.  CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells , 2006, The Journal of experimental medicine.

[13]  A. Silman,et al.  Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. , 2006, Arthritis and rheumatism.

[14]  J. Isaacs,et al.  Outcome of intensive immunosuppression and autologous stem cell transplantation in patients with severe rheumatoid arthritis is associated with the composition of synovial T cell infiltration , 2005, Annals of the rheumatic diseases.

[15]  A. Herbelin,et al.  NKT cell status and IL-10-dependent therapeutic effect of NKT cell stimulation on collagen-arthritis in DBA/1 mice , 2005, Arthritis Research & Therapy.

[16]  Andrew K. Brown,et al.  Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopenia , 2004, Arthritis research & therapy.

[17]  M. Uffmann,et al.  Patients and Methods , 2022 .

[18]  J. Jacobs,et al.  A good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow up , 2004, Annals of the rheumatic diseases.

[19]  P. Emery,et al.  Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention. , 2003, Clinical and experimental rheumatology.

[20]  T. Nomura,et al.  Control of Regulatory T Cell Development by the Transcription Factor Foxp3 , 2002 .

[21]  P. Emery,et al.  Dysregulated lymphocyte proliferation and differentiation in patients with rheumatoid arthritis. , 2002, Blood.

[22]  Clare Baecher-Allan,et al.  Inhibition of Human CD4+CD25+high Regulatory T Cell Function1 , 2002, The Journal of Immunology.

[23]  M. Salmon,et al.  The role of T-lymphocytes in rheumatoid arthritis. , 1995, British medical bulletin.

[24]  P. Emery,et al.  Subpopulations of primed T helper cells in rheumatoid arthritis. , 1993, Arthritis and rheumatism.

[25]  G. Kingsley,et al.  The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. , 1992, Arthritis and rheumatism.

[26]  H. Jasin,et al.  Interactions between anticollagen antibodies and chondrocytes. , 1992, Arthritis and rheumatism.

[27]  F. Epstein,et al.  Rheumatoid arthritis. Pathophysiology and implications for therapy. , 1990, The New England journal of medicine.

[28]  P. Gregersen,et al.  The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. , 1987, Arthritis and rheumatism.

[29]  S SmolenJosef,et al.  EULAR (欧州リウマチ学会) 合成および疾患修飾性抗リウマチ生物学的製剤による関節リウマチ管理に関する推奨ガイドライン | 文献情報 | J-GLOBAL 科学技術総合リンクセンター , 2010 .

[30]  G. Burmester,et al.  Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study. , 2008, Arthritis and rheumatism.

[31]  M. Pillinger.  Very Early Treatment With Infliximab in Addition to Methotrexate in Early, Poor-Prognosis Rheumatoid Arthritis Reduces Magnetic Resonance Imaging Evidence of Synovitis and Damage, With Sustained Benefit After Infliximab Withdrawal: Results From a Twelve-Month Randomized, Double-blind, Placebocontrol , 2006 .

[32]  Alexander Fraser,et al.  Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-contro , 2005, Arthritis and rheumatism.

[33]  Michael J. Green,et al.  Elucidation of the relationship between synovitis and bone damage: a randomized magnetic resonance imaging study of individual joints in patients with early rheumatoid arthritis. , 2003, Arthritis and rheumatism.

[34]  A. Silman,et al.  Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study. , 2003, Arthritis and rheumatism.

[35]  P. Emery,et al.  IL-7 Deficiency and Prolonged Therapy-Induced Lymphopenia in Rheumatoid Arthritis. , 2003 .

[36]  J J Anderson,et al.  Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. , 2000, Arthritis and rheumatism.

[37]  A. Silman,et al.  Does the age of onset of rheumatoid arthritis influence phenotype?: a prospective study of outcome and prognostic factors. , 2000, Rheumatology.

[38]  R. Winchester.  The molecular basis of susceptibility to rheumatoid arthritis. , 1994, Advances in immunology.